Industry Wire 214

September 27, 2024 Jake Fishman 0 min read
  1. LAPD officer’s gun sucked into MRI machine during raid.
  2. Dems introduce legislation to permanently lower ACA plan costs. 
  3. Cardinal Health acquires Integrated Oncology Network for $1B.
  4. CDC: 40.3% of U.S adults are obese, 46.5% of adults aged 40-59.
  5. VA’s new Oracle EHR saw 826 ‘major’ incidents since its launch.
  6. U.S. House committee passes rare pediatric disease drug bill.
  7. 29% of Americans have undiagnosed iron deficiency.
  8. Senate holds Steward Health CEO in criminal contempt.
  9. PA-based system fires workers for sharing inappropriate patient images.
  10. Providers say reimbursement denials are getting worse.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiogenetics January 12, 2026

Y Chromosome Loss and MI Risk January 12, 2026

We already know that loss or mutation in genes can lead to increased cardiovascular risk or even cause some diseases, but what about losing a whole chromosome? New research in JACC suggests that men who lose pieces of their Y chromosome as they age could be at greater risk of heart attacks. Researchers measured the […]

Cardiology Testing January 8, 2026

HF Frailty Could Be Simpler than We Think January 8, 2026

A new registry analysis out of Japan suggests we may be able to simplify how we classify heart failure frailty without losing accuracy, allowing us to screen for HF mortality risk in faster and more practical ways. To see how CFS stacks up against comprehensive physical testing, researchers categorized 3.9k patients hospitalized with HF into […]

Cardiology Pharmaceuticals January 5, 2026

Aficamten Approved, Enter a New HCM Contender January 5, 2026

After years of dedicated research and careful science, Cytokinetics’ aficamten (Myqorzo) is officially FDA approved for obstructive hypertrophic cardiomyopathy, marking the company’s first-ever regulatory approval and ending BMS mavacamten’s reign as the only oHCM treatment. The FDA’s decision stemmed from the SEQUOIA-HCM trial, which demonstrated aficamten’s efficacy over 24 weeks in symptomatic obstructive HCM patients […]